Tenax Therapeutics Announces New US Patent Covering The Use Of Levosimendan In Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction, The New Patent Provides Protections Through December 2040
Portfolio Pulse from Benzinga Newsdesk
Tenax Therapeutics has been granted a new US patent for the use of Levosimendan in treating pulmonary hypertension associated with heart failure with preserved ejection fraction, extending its protections until December 2040.
April 30, 2024 | 11:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The new patent for Levosimendan significantly strengthens Tenax Therapeutics' intellectual property portfolio, potentially enhancing its market position and future revenue prospects in the treatment of pulmonary hypertension.
The granting of a new patent for Levosimendan by Tenax Therapeutics directly impacts the company by potentially increasing its market exclusivity and protecting its competitive edge in the treatment of pulmonary hypertension until 2040. This could lead to increased investor confidence and a positive outlook on the company's future revenue streams and market position.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100